CN116669575B - 作为胃促生长素受体激动剂的三唑化合物的用途 - Google Patents

作为胃促生长素受体激动剂的三唑化合物的用途 Download PDF

Info

Publication number
CN116669575B
CN116669575B CN202180076726.1A CN202180076726A CN116669575B CN 116669575 B CN116669575 B CN 116669575B CN 202180076726 A CN202180076726 A CN 202180076726A CN 116669575 B CN116669575 B CN 116669575B
Authority
CN
China
Prior art keywords
receptor
amino
diol
propane
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180076726.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN116669575A (zh
Inventor
裵宰晟
陈喜庆
朴敏喜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingbei University School Industry University Cooperative Force
Original Assignee
Qingbei University School Industry University Cooperative Force
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingbei University School Industry University Cooperative Force filed Critical Qingbei University School Industry University Cooperative Force
Priority to CN202510489733.4A priority Critical patent/CN120081796A/zh
Publication of CN116669575A publication Critical patent/CN116669575A/zh
Application granted granted Critical
Publication of CN116669575B publication Critical patent/CN116669575B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN202180076726.1A 2020-09-22 2021-09-17 作为胃促生长素受体激动剂的三唑化合物的用途 Active CN116669575B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510489733.4A CN120081796A (zh) 2020-09-22 2021-09-17 作为胃促生长素受体激动剂的三唑化合物的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200122540 2020-09-22
KR10-2020-0122540 2020-09-22
PCT/KR2021/012823 WO2022065831A1 (ko) 2020-09-22 2021-09-17 그렐린 수용체 작용제로서의 트리아졸 화합물의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510489733.4A Division CN120081796A (zh) 2020-09-22 2021-09-17 作为胃促生长素受体激动剂的三唑化合物的用途

Publications (2)

Publication Number Publication Date
CN116669575A CN116669575A (zh) 2023-08-29
CN116669575B true CN116669575B (zh) 2025-04-04

Family

ID=80845629

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180076726.1A Active CN116669575B (zh) 2020-09-22 2021-09-17 作为胃促生长素受体激动剂的三唑化合物的用途
CN202510489733.4A Pending CN120081796A (zh) 2020-09-22 2021-09-17 作为胃促生长素受体激动剂的三唑化合物的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510489733.4A Pending CN120081796A (zh) 2020-09-22 2021-09-17 作为胃促生长素受体激动剂的三唑化合物的用途

Country Status (6)

Country Link
US (1) US12570617B2 (https=)
EP (1) EP4218757A4 (https=)
JP (1) JP7799262B2 (https=)
KR (1) KR102752714B1 (https=)
CN (2) CN116669575B (https=)
WO (1) WO2022065831A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022448086B2 (en) * 2022-03-23 2024-02-01 Nextgen Bioscience Co., Ltd. Pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for s1pr1 and s1pr4

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019212196A1 (ko) * 2018-04-30 2019-11-07 경북대학교 산학협력단 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
ES2388501T3 (es) * 2004-08-12 2012-10-16 Helsinn Healthcare S.A. Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal
US10975070B2 (en) * 2010-02-26 2021-04-13 Raqualia Pharma Inc. Ghrelin receptor agonist for treatment of cachexia
EP2431035A1 (en) * 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
KR20150020602A (ko) * 2012-05-25 2015-02-26 라퀄리아 파마 인코포레이티드 무산증 치료를 위한 그렐린 수용체 효능물질
ES2864079T3 (es) * 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2017075535A1 (en) * 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
KR101830244B1 (ko) * 2016-01-20 2018-02-21 서울대학교 산학협력단 신규한 헤테로방향족 고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 s1p 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
KR20180036318A (ko) 2016-09-30 2018-04-09 경북대학교 산학협력단 2-아미노-2-(1-도데실-1h-1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체를 유효성분으로 포함하는 퇴행성 신경질환 및 우울증 예방 또는 치료용 약학적 조성물
KR102292989B1 (ko) 2017-03-29 2021-08-26 재단법인 아산사회복지재단 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물
KR102609693B1 (ko) 2019-04-18 2023-12-05 현대모비스 주식회사 차량의 전원 백업 장치

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019212196A1 (ko) * 2018-04-30 2019-11-07 경북대학교 산학협력단 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도
CN112351974A (zh) * 2018-04-30 2021-02-09 庆北大学校产学协力团 直接抑制asm活性的新型化合物2-氨基-2-（1,2,3-三唑-4-基）-1,3-丙二醇衍生物及其应用

Also Published As

Publication number Publication date
CN116669575A (zh) 2023-08-29
EP4218757A1 (en) 2023-08-02
JP7799262B2 (ja) 2026-01-15
US12570617B2 (en) 2026-03-10
US20230339869A1 (en) 2023-10-26
WO2022065831A1 (ko) 2022-03-31
KR102752714B1 (ko) 2025-01-10
JP2023542964A (ja) 2023-10-12
CN120081796A (zh) 2025-06-03
EP4218757A4 (en) 2024-11-13
KR20220039625A (ko) 2022-03-29

Similar Documents

Publication Publication Date Title
JP2023164877A (ja) セラストロールの類似体
RU2759856C1 (ru) Новое соединение для прямого ингибирования активности asm, представляющее собой производное 2-амино-2-(1,2,3-триазол-4-ил)пропан-1,3-диола, и его применение
WO1995008995A1 (en) Antiobestic agent
CN116669575B (zh) 作为胃促生长素受体激动剂的三唑化合物的用途
EP3423461A1 (en) Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
US7081473B2 (en) Agent for preventing/ameliorating obesity comprising methylidene hydrizide compound as active ingredient
EP3621619B1 (en) Compounds and methods for treatment of visceral pain
EP3020399A1 (en) Novel pharmaceutical composition for preventing or treating cancer
WO2019244937A1 (ja) ロズマリン酸誘導体又はその塩
CN114302881B (zh) 适用于治疗和预防肌肉萎缩和其他状况的化合物
WO2013073698A1 (ja) Cxcr4活性阻害ペプチド及びその用途
CN1681514A (zh) 一种治疗糖尿病,包括与糖尿病有关的疾病和糖尿病并发症的方法
KR100886466B1 (ko) 신규한 스티그마스테롤 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법, 및 이를 포함하는 비만억제 또는 고지혈증 예방 및 치료용 조성물
WO2018199562A1 (ko) 신규 화합물 2-아미노-2-(1-(2-(2-히드록시에톡시)에틸)-1h-1，2,3-트리아졸- 4-일)프로판 -1,3-디올 유도체 및 이의 용도
KR20080069233A (ko) 위장관 기능 촉진제
JP5801572B2 (ja) ＰＰＡＲγ活性化剤
JP2018177738A (ja) Ｔｒｐｖ４活性抑制剤
JP7185226B2 (ja) １，５－アンヒドロフルクトース誘導体を含むａｍｐｋ活性化剤
KR20220151044A (ko) 바이구아나이드 약물을 이용한 대사 이상 동반된 mcp1 과도 활성 골관절염 질환 치료 주사 조성물
EP1366052B1 (en) Novel multi-ring organic compounds for regulating gut motility and food intake
JP2026506941A (ja) Ｇタンパク質共役型受容体を調節するための組成物および方法
CN109879839B (zh) 6-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途
KR20250095953A (ko) 귀리껍질 추출물을 포함하는 근육질환 예방, 개선 또는 치료용 조성물
KR20250030254A (ko) 담즙산 및 양전하 기반 펩타이드를 포함하는 대사성 질환 예방 및 치료용 약학적 조성물
US20040102514A1 (en) Novel multi-ring organic compounds for regulating gut motility and food intake

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant